CIRCULATING IRISIN LEVEL IN DIAGNOSED PATIENTS WITH METABOLIC SYNDROME

Rojeen Rashid Suleiman

Rojeen Rashid Suleiman Lecture at college of health and medical techniques ,sheckhan , duhok polytechnic university

Keywords: Serum irisin, Metabolic syndrome, Obesity, Diabetes mellitus, Serum triglyceride

Abstract

https://doi.org/10.31386/dmj.2024.18.2.7

Background: Metabolic syndrome is characterized by reversible diagnostic components such as reduced serum HDL-cholesterol, raised serum triglycerides, increase serum glucose concentration, increase blood pressure, all of which are related to large waist circumference. Irisin is an adipokine hormone that is mostly secreted by white subcutaneous adipose tissue and has a critical regulatory function in lipid metabolism. The present study aimed to evaluate serum irisin level among metabolic syndrome.

Materials and methods: A case control study was conducted among138 individuals, 69 patients with metabolic syndrome and 69 healthy individuals as a control group. The study was conducted from June 2022 to June 2023After a night of fasting, blood samples were taken the next morning. Glucose, insulin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and blood HbA1c% were all determined using the Cobas 6000 (Hitachi, Roche) device, with the exception of serum irisin, which was determined using an ELISA.

Results: The MS participants have higher percentage of high irisin levels compared to control participants with statistically significant differences (37 (53.6%); 24 (34.8%); p=0.039). Furthermore; there were insignificant differences between the mean ±SD levels of serum irisin of the studied groups (p=0.220).

Conclusion: Mean serum irisin level was higher among MS patients compared to healthy individuals, as well as, serum irisin levels had a positive correlation with isolated component of MS such as waist circumference, dyslipidemia and impaired glucos e metabolism.

Downloads

Download data is not yet available.

References

REFERENCES
[1] T. S. Han and M. E. Lean, "Metabolic syndrome," Medicine, vol. 43, no. 2, pp. 80-87, 2015.
[2] Suleiman RR, Salih SF, Abdullah BI, IbrahimIH, Saeed ZA. Triglyceride glucose index, its modified indices, and triglyceride HDL-C ratio as predictor markers of insulin resistance in prediabetic individuals. Med J Babylon 2023;20:268-73.
[3] K. G. M. M. Alberti, P. Zimmet, and J. Shaw, "Metabolic syndrome—a new world‐wide definition. A consensus statement from the international diabetes federation," Diabetic medicine, vol. 23, no. 5, pp. 469-480, 2006.
[4] I. S. PITY, D. J. AL-TIMIMI, and S. F. SALIH, "METABOLIC SYNDROME AND COLORECTAL CANCER IN DUHOK, KURDISTAN IRAQ," Duhok Medical Journal, vol. 10, no. 2, 2016.
[5] N. Chen, Q. Li, J. Liu, and S. Jia, "Irisin, an exercise‐induced myokine as a metabolic regulator: an updated narrative review," Diabetes/metabolism research and reviews, vol. 32, no. 1, pp. 51-59, 2016.
[6] K. Hee Park et al., "Circulating irisin in relation to insulin resistance and the metabolic syndrome," The journal of clinical endocrinology & metabolism, vol. 98, no. 12, pp. 4899-4907, 2013.
[7] J.-J. Liu et al., "Lower circulating irisin is associated with type 2 diabetes mellitus," Journal of Diabetes and its Complications, vol. 27, no. 4, pp. 365-369, 2013.
[8] [E. Nigro et al., "Adiponectin profile and Irisin expression in Italian obese children: Association with insulin-resistance," Cytokine, vol. 94, pp. 8-13, 2017.
[9] K. Hee Park et al., "Circulating irisin in relation to insulin resistance and the metabolic syndrome," The journal of clinical endocrinology & metabolism, vol. 98, no. 12, pp. 4899-4907, 2013.
[10] S. Zhao et al., "Association between macro-and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study," Cardiovascular diabetology, vol. 18, no. 1, pp. 1-8, 2019.
[11] H. A. Rajab, S. F. Salih, H. M. Hasan, and D. J. Al-Timimi, "Vitamin D status among subjects with metabolic syndrome attending primary health care centers in Duhok, Kurdistan region,(Iraq)," JABHS-Journal of the Arab Board of Health Specializations, vol. 20, no. 3, pp. 3-8, 2019.
[12] R. R. Suleiman, S. F. Salih, B. I. Abdullah, I. H. Ibrahim, and Z. A. Saeed, "Triglyceride glucose index, its modified indices, and triglyceride HDL-C ratio as predictor markers of insulin resistance in prediabetic individuals," Medical Journal of Babylon, vol. 20, no. 2, p. 268, 2023.
[13] N. C. E. P. E. P. o. Detection and T. o. H. B. C. i. Adults, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (no. 2). The Program, 2002.
[14] T. A. Jacobson et al., "National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report," Journal of clinical lipidology, vol. 9, no. 2, pp. 129-169, 2015.
[15] S. H. Beigh and S. Jain, "Prevalence of metabolic syndrome and gender differences," Bioinformation, vol. 8, no. 13, p. 613, 2012.
[16] M. A. Njelekela et al., "Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania," BMC cardiovascular disorders, vol. 9, pp. 1-8, 2009.
[17] F. Jahan, R. Qureshi, T. Borhany, and H. B. Hamza, "Metabolic syndrome: frequency and gender differences at an out-patient clinic," Journal of the College of Physicians and Surgeons Pakistan, vol. 17, no. 1, p. 32, 2007.
[18] V. Regitz-Zagrosek, E. Lehmkuhl, and M. O. Weickert, "Gender differences in the metabolic syndrome and their role for cardiovascular disease," Clinical Research in Cardiology, vol. 95, pp. 147-147, 2006.
[19] J. Y. Huh, F. Dincer, E. Mesfum, and C. Mantzoros, "Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans," International journal of obesity, vol. 38, no. 12, pp. 1538-1544, 2014.
[20] N. Perakakis et al., "Physiology and role of irisin in glucose homeostasis," Nature reviews endocrinology, vol. 13, no. 6, pp. 324-337, 2017.
[21] L. I. Arhire, L. Mihalache, and M. Covasa, "Irisin: a hope in understanding and managing obesity and metabolic syndrome," Frontiers in endocrinology, vol. 10, p. 524, 2019.
[22] N. Chen, Q. Li, J. Liu, and S. Jia, "Irisin, an exercise‐induced myokine as a metabolic regulator: an updated narrative review," Diabetes/metabolism research and reviews, vol. 32, no. 1, pp. 51-59, 2016.
[23] A. Stengel, T. Hofmann, M. Goebel-Stengel, U. Elbelt, P. Kobelt, and B. F. Klapp, "Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index," Peptides, vol. 39, pp. 125-130, 2013.
[24] C.-Z. Wu et al., "The relationship of irisin with metabolic syndrome components and insulin secretion and resistance in schoolchildren," Medicine, vol. 100, no. 5, 2021.
[25] I. Ibrahim and S. Salih, "Serum Irisin In Individuals with Type 2 Diabetes Mellitus and Prediabetes in Duhok City," Journal of Life and Bio Sciences Research, vol. 3, no. 02, pp. 59-64, 2022.
[26] C. Xin et al., "Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway," International journal of obesity, vol. 40, no. 3, pp. 443-451, 2016.
[27] S. Mehrabian, E. Taheri, M. Karkhaneh, M. Qorbani, and S. Hosseini, "Association of circulating irisin levels with normal weight obesity, glycemic and lipid profile," Journal of Diabetes & Metabolic Disorders, vol. 15, pp. 1-6, 2015.
[28] R. Liu et al., "Inverse correlation between serum irisin and cardiovascular risk factors among Chinese overweight/obese population," BMC cardiovascular disorders, vol. 21, no. 1, pp. 1-8, 2021.